Anoestrus in the dog: a fascinating story.
In the bitch, progression from early to late anoestrus is characterized by a higher amplitude and a larger number of gonadotrophin-releasing hormone (GnRH) pulses generated by the hypothalamus, an increase in the sensitivity of the pituitary to GnRH, and an increase in ovarian responsiveness to gonadotrophins. An increase in basal plasma follicle-stimulating hormone (FSH) concentration is a critical event required for initiation of folliculogenesis. A period of increased luteinizing hormone pulsatility has been reported shortly before the onset of pro-oestrus. Apart from these changes in the hypothalamic-pituitary-ovarian axis, there is also involvement of dopaminergic influences in the initiation of a new follicular phase in the bitch. Administration of the dopamine-agonists bromocriptine and cabergoline shortens the anoestrus and is associated with a decrease in the plasma prolactin concentration, suggesting that the shortened anoestrus is the result of suppression of prolactin secretion. Yet, the anoestrus is not shortened in bitches treated with metergoline, a drug, which in a low dosage lowers the plasma prolactin concentration via a serotonin-antagonistic pathway. In addition, under physiological conditions low plasma prolactin concentrations are found during the entire anoestrus. Furthermore, a low dosage of bromocriptine, insufficient to cause a decrease in the plasma prolactin concentration, prematurely induces folliculogenesis. These observations indicate that not the decrease in the plasma prolactin concentration, but another dopamine-agonistic influence plays a critical role in the transition to a new follicular phase. The dopamine-agonist induced shortening of the anoestrus is associated with a rapid rise in the basal plasma FSH concentration, similar to what is observed during the physiological late anoestrus. This observation underlines the importance of an increase in the circulating plasma FSH concentration in the initiation of folliculogenesis in the bitch.
Okkens
A C
AC
Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. a.c.shaefers@vet.uu.nl
Kooistra
H S
HS
D000780:Anestrus / Q000097:blood / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D001971:Bromocriptine; D004285:Dogs / Q000097:blood / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D030762:Estrous Cycle / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood; D012636:Secretory Rate; D012702:Serotonin Antagonists / Q000494:pharmacology*
D018491:Dopamine Agonists; D006065:Gonadotropins, Pituitary; D012702:Serotonin Antagonists; D001971:Bromocriptine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone